{"id":"NCT01655069","sponsor":"Astellas Pharma Europe B.V.","briefTitle":"A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076","officialTitle":"An Open-Label, Long-Term Extension, Multi-center, Sequential Dose Titration Study to Assess Safety and Efficacy of Solifenacin Succinate Suspension in Pediatric Subjects With Overactive Bladder (OAB)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-10-04","primaryCompletion":"2014-10-08","completion":"2014-10-08","firstPosted":"2012-08-01","resultsPosted":"2017-12-11","lastUpdate":"2024-11-13"},"enrollment":148,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Urinary Bladder, Overactive"],"interventions":[{"type":"DRUG","name":"Solifenacin succinate suspension","otherNames":["YM905","solifenacin succinate"]}],"arms":[{"label":"Children Treated with Placebo in 905-CL-076","type":"EXPERIMENTAL"},{"label":"Children Treated with Solifenacin in 905-CL-076","type":"EXPERIMENTAL"},{"label":"Adolescents Treated with Placebo in 905-CL-076","type":"EXPERIMENTAL"},{"label":"Adolescents Treated with Solifenacin in 905-CL-076","type":"EXPERIMENTAL"}],"summary":"This was a 40-week study to investigate how safe and effective solifenacin solution was in treating children or adolescents with symptoms of overactive bladder (OAB), who completed study 905-CL-076 (NCT01565707).","primaryOutcome":{"measure":"Number of Participants With and Severity of Treatment-Emergent Adverse Events (TEAEs)","timeFrame":"From first dose of solifenacin (in Study 905-CL-076 or in current study) up to 7 days after last dose of open-label solifenacin (41 weeks for participants who received placebo in 076 and 53 weeks for those who received solifenacin in 076).","effectByArm":[{"arm":"Children (Aged 5 to Less Than 12 Years)","deltaMin":72,"sd":null},{"arm":"Adolescents (Aged 12 to Less Than 18 Years)","deltaMin":10,"sd":null}],"pValues":[]},"eligibility":{"minAge":"5 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":39,"countries":["United States","Belgium","Brazil","Canada","Denmark","Mexico","Norway","Philippines","Poland","Serbia and Montenegro","South Africa","South Korea","Sweden","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002047-10/results","https://astellasclinicalstudyresults.com/study.aspx?ID=244"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":118},"commonTop":["Nasopharyngitis","Headache","Constipation","Electrocardiogram QT prolonged","Gastroenteritis"]}}